LA JOLLA—Every week, there seems to be another story about the health benefits of running. That’s great—but what if you can’t run? For the elderly, obese or otherwise mobility-limited, the rewards of aerobic exercise have long been out of reach.
LA JOLLA—FedEx, UPS, DHL—when it comes to sending packages, choices abound. But the most important delivery service you may not have heard of? mRNA. That’s short for messenger RNA, which is how your DNA sends blueprints to the protein-assembly factories of your cells. When a protein is faulty, delivering synthetic mRNA to cells could trigger production of a functional version. And that’s a message people with a variety of genetic diseases want to hear.
LA JOLLA—At noon every day, levels of genes and proteins throughout your body are drastically different than they are at midnight. Disruptions to this 24-hour cycle of physiological activity are why jet lag or a bad night’s sleep can alter your appetite and sleep patterns for days—and even contribute to conditions like heart disease, sleep disorders and cancers.
LA JOLLA—A molecular pathway that is activated in the brain during fasting helps halt the spread of intestinal bacteria into the bloodstream, according to a new study by a team of researchers at the Salk Institute.
LA JOLLA—Salk scientists have solved a longstanding problem in the effort to create replacement cells for diabetic patients. The team uncovered a hidden energy switch that, when flipped, powers up pancreatic cells to respond to glucose, a step that eluded previous research. The result is the production of hundreds of millions of lab-produced human beta cells—able to relieve diabetes in mice.
LA JOLLA—A team led by scientists at The Scripps Research Institute (TSRI) and the Salk Institute for Biological Studies has discovered two enzymes that appear to play a role in metabolism and inflammation—and might someday be targeted with drugs to treat type 2 diabetes and inflammatory disorders.
LA JOLLA—The Salk Institute has named Professor Reuben Shaw as the new director of Salk’s National Cancer Institute-designated Cancer Center. Shaw is a member of Salk’s Molecular and Cell Biology Laboratory and the holder of the William R. Brody Chair.
LA JOLLA—Diabetes is often the result of obesity and poor diet choices, but for some older adults the disease might simply be a consequence of aging. New research has discovered that diabetes—or insulin resistance—in aged, lean mice has a different cellular cause than the diabetes that results from weight gain (type 2). And the findings point toward a possible cure for what the co-leading scientists, Ronald Evans and Ye Zheng, are now calling a new kind of diabetes (type 4).
LA JOLLA, CA—The Salk Institute will co-lead a new transatlantic ‘Dream Team’ of researchers that will launch a fresh attack on pancreatic cancer, one of the deadliest forms of cancer on both sides of the Atlantic. Stand Up To Cancer (SU2C), Cancer Research UK, and The Lustgarten Foundation selected the team and will provide $12 million in funding over three years.
LA JOLLA–Mice that have a genetic version of mitochondrial disease can easily be mistaken for much older animals by the time they are nine months old: they have thinning grey hair, osteoporosis, poor hearing, infertility, heart problems and have lost weight. Despite having this disease at birth, these mice have a “secret weapon” in their youth that staves off signs of aging for a time.
LA JOLLA–Salk researchers have developed an entirely new type of pill that tricks the body into thinking it has consumed calories, causing it to burn fat. The compound effectively stopped weight gain, lowered cholesterol, controlled blood sugar and minimized inflammation in mice, making it an excellent candidate for a rapid transition into human clinical trials.
LA JOLLA–Scientists at the Salk Institute and Beth Israel Deaconess Medical Center (BIDMC) in Boston have discovered a new class of molecules–produced in human and mouse fat–that protects against diabetes.
LA JOLLA—In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. The discovery by Salk scientists, published today in the journal Nature, could lead to a new generation of safer, more effective diabetes drugs.
LA JOLLA—The Salk Institute is pleased to welcome a new full professor and three new assistant professors, all exceptional leaders in their respective fields. The new faculty will facilitate innovative and collaborative breakthroughs in understanding human health and disease.
LA JOLLA—For most people, the urge to eat a meal or snack comes at a few, predictable times during the waking part of the day. But for those with a rare syndrome, hunger comes at unwanted hours, interrupts sleep and causes overeating.
LA JOLLA—The Salk Institute has received a $3 million gift from the Glenn Foundation for Medical Research to allow the Institute to continue conducting research to understand the biology of normal human aging and age-related diseases.
LA JOLLA—Reuben Shaw, a member of the Salk Institute’s Molecular and Cell Biology Laboratory and a Howard Hughes Medical Institute early career scientist, has been promoted from associate professor to full professor.
After a rigorous evaluation process by Salk senior faculty, non-resident fellows and scientific peers, the promotion was announced Friday.
LA JOLLA, CA—A new approach to mapping how proteins interact with each other, developed at the Salk Institute for Biological Studies, could aid in the design of new drugs for diseases such as diabetes and osteoporosis. By reengineering proteins using artificial amino acids, the Salk scientists determine the detailed molecular structure of a cellular
switch and its ligand, the molecule that turns it on. The switch—corticotrophin releasing factor type 1
(CRF1R)—belongs to a class of cellular receptors whose structures are notoriously hard to determine. These receptors regulate processes throughout the body and are involved in many diseases.
LA JOLLA, CA—The Juvenile Diabetes Research Foundation (JDRF) has given Salk scientist Mark Huising a five-year, $750,000 Career Development Award for his proposed study on how a novel network of receptors in human islets receives and integrates molecular signals. In pre-clinical models, activation of these receptors has proven to actually prevent diabetes. Career Development Awards are highly competitive and bestowed upon only a handful of people each year.
LA JOLLA, CA—The American Association for Cancer Research (AACR), the world’s oldest and largest professional organization dedicated to accelerating scientific progress to prevent and cure cancer, has selected four Salk scientists and two of the Institute’s non-resident fellows to be inducted in its first class of the fellows of the AACR Academy.
LA JOLLA, CA—A team of scientists, including researchers from the Salk Institute for Biological Studies, has discovered that a drug used to treat canker sores appears to reverse obesity in mice. The findings, published February 10 in Nature Medicine, may lead to new weight-loss medications that could have an impact on growing obesity and diabetes rates in the United States.
The drug, amlexanox, has been on the market for more than 15 years. Different formulations of the drug are used in Japan to treat asthma and in the United States to treat canker sores. Human clinical trials for weight loss are expected to begin later this year.
LA JOLLA, CA—You might think you have nothing in common with mustard except hotdogs. Yet based on research in a plant from the mustard family, Salk scientists have discovered a possible explanation for how organisms, including humans, directly regulate chemical reactions that quickly adjust the growth of organs. These findings overturn conventional views of how different body parts coordinate their growth, shedding light on the development of more productive plants and new therapies for metabolic diseases.
LA JOLLA, CA—Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.
LA JOLLA, CA—The Salk Institute for Biological Studies has received a $42 million gift-the largest in the Institute’s history-to establish the Helmsley Center for Genomic Medicine (HCGM), a research center dedicated to decoding the common genetic factors underlying many complex chronic human diseases.
LA JOLLA, CA—When it’s dark, and we start to fall asleep, most of us think we’re tired because our bodies need rest. Yet circadian rhythms affect our bodies not just on a global scale, but at the level of individual organs, and even genes.
LA JOLLA, CA—Growing evidence suggests that there may be a link between diabetes and Alzheimer’s disease, but the physiological mechanisms by which diabetes impacts brain function and cognition are not fully understood. In a new study published in Aging Cell, researchers at the Salk Institute for Biological Studies show, for the first time, that diabetes enhances the development of aging features that may underlie early pathological events in Alzheimer’s.
LA JOLLA, CA—Scientists have known for some time that throwing off the body’s circadian rhythm can negatively affect body chemistry. In fact, workers whose sleep-wake cycles are disrupted by night shifts are more susceptible to chronic inflammatory diseases such as diabetes, obesity and cancer.
LA JOLLA, CA—With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science. A number of hurdles, both scientific and non-scientific, however, have precluded scientists from reaching the holy grail of using these special cells to treat heart disease, diabetes, Alzheimer’s and other diseases.
LA JOLLA, CA—It turns out that when we eat may be as important as what we eat. Scientists at the Salk Institute for Biological Studies have found that regular eating times and extending the daily fasting period may override the adverse health effects of a high-fat diet and prevent obesity, diabetes and liver disease in mice.
LA JOLLA, CA—Humans are built to hunger for fat, packing it on during times of feast and burning it during periods of famine. But when deluged by foods rich in fat and sugar, the modern waistline often far exceeds the need to store energy for lean times, and the result has been an epidemic of diabetes, heart disease and other obesity-related problems.
LA JOLLA, CA—In their extraordinary quest to decode human metabolism, researchers at the Salk Institute for Biological Studies have discovered a pair of molecules that regulates the liver’s production of glucose—the simple sugar that is the source of energy in human cells and the central player in diabetes.
LA JOLLA, CA—The discovery of a major gear in the biological clock that tells the body when to sleep and metabolize food may lead to new drugs to treat sleep problems and metabolic disorders, including diabetes.
LA JOLLA, CA—Faculty members Reuben Shaw and Lei Wang, have been promoted to the position of Associate Professor at the Salk Institute after a rigorous evaluation process by Salk senior faculty, Non-Resident Fellows, and scientific peers. The career milestone distinguishes these two investigators as leading authorities in their respective disciplines who have made original, innovative and notable contributions to biological research.
LA JOLLA, CA—Salk Institute scientist Ronald Evans has been selected as the recipient of the prestigious 2012 Wolf Prize in Medicine, Israel’s highest award for achievements benefiting mankind. According to the Wolf Prize jury, Evans was selected for his discovery of the gene super-family encoding nuclear receptors and elucidating the mechanism of action of this class of receptors.
LA JOLLA, CA—Scientists have discovered a missing link between the body’s biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.